2. Autophagy Apoptosis
  3. Autophagy Apoptosis Caspase Bcl-2 Family
  4. TBC1D2-IN-1

TBC1D2-IN-1 is a potent orally active and selective TBC1D2 inhibitor with a Kd of 1.1 μM. TBC1D2-IN-1 selectively inhibits TBC1D2-mediated GTP hydrolysis on RAB7A-GTP, promotes RAB7A accumulation on lysosomal membranes, and induces apoptosis and autophagy. TBC1D2-IN-1 exerts selective antiproliferative activity cancer cells. TBC1D2-IN-1 can be used for the research of cervical carcinoma.

For research use only. We do not sell to patients.

TBC1D2-IN-1

TBC1D2-IN-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

TBC1D2-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TBC1D2-IN-1 is a potent orally active and selective TBC1D2 inhibitor with a Kd of 1.1 μM. TBC1D2-IN-1 selectively inhibits TBC1D2-mediated GTP hydrolysis on RAB7A-GTP, promotes RAB7A accumulation on lysosomal membranes, and induces apoptosis and autophagy. TBC1D2-IN-1 exerts selective antiproliferative activity cancer cells. TBC1D2-IN-1 can be used for the research of cervical carcinoma[1].

IC50 & Target[1]

Caspase-3

 

Bax

 

Bcl-2

 

In Vitro

TBC1D2-IN-1 (compound A1) (0.1-20 μM) binds selectively to the PH domain of TBC1D2, showing weaker binding to Top 1 and no binding to Hsp90[1].
TBC1D2-IN-1 (2 days) potently and selectively inhibits proliferation of HeLa cells with an IC50 of 0.43 μM and inhibits proliferation of A549, HepG2, and BEAS-2B cells with IC50 values of 0.56, 0.79, and 1.5 μM, respectively[1].
TBC1D2-IN-1 (0.5-1.5 μM; 24 h) induces dose-dependent accumulation of RAB7A on the lysosomal membrane of HeLa cells[1].
TBC1D2-IN-1 (0.5-2 μM; 48 h) induces concentration-dependent upregulation of RAB7A protein levels in HeLa cells[1].
TBC1D2-IN-1 (0.5-2 μM; 48 h) induces concentration-dependent decreases in TBC1D2 and VEGFR2 protein levels in HeLa cells after 48 h of treatment, with no significant effects on Top 1 or Hsp90 levels[1].
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) induces potent autophagy in HeLa cells[1].
TBC1D2-IN-1 (0.1-10 μM; 1 h) induces a biphasic change in TBC1D2 protein levels in HeLa cells[1].
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) induces a triphasic apoptotic response in HeLa cells[1].
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) induces a non-monotonic change in the G2/M phase fraction of HeLa cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TBC1D2-IN-1 Related Antibodies

Immunofluorescence[1]

Cell Line: HeLa cells
Concentration: 0.5; 1.5 μM
Incubation Time: 24 h
Result: Induced dose-dependent accumulation of RAB7A on the lysosomal membrane, visible as distinct punctate staining in treated cells compared to the diffuse cytoplasmic staining in control cells.

Western Blot Analysis[1]

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2 μM
Incubation Time: 48 h
Result: Induced a concentration-dependent increase in RAB7A protein levels.
Caused a statistically significant 2.2-fold increase in RAB7A protein levels at 2 μM compared to control.\n
Induced a concentration-dependent decrease in TBC1D2 and VEGFR2 protein levels.
Caused no significant changes in Top 1 or Hsp90 protein levels.\n
Induced dynamic changes in apoptotic regulators: p53 levels showed a modest initial increase followed by a decrease, caspase-3 and Bcl-2 levels progressively declined, and Bax levels initially decreased then markedly increased at 2 μM.

Cell Autophagy Assay[1]

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2; 2.5 μM
Incubation Time: 24 h
Result: Induced a biphasic response in lysosomal fluorescence intensity: fluorescence increased in a concentration-dependent manner up to 1.5 μM, with a 40-fold increase relative to control, then decreased at 2.5 μM due to lysosomal impairment from apoptosis.

Immunofluorescence[1]

Cell Line: HeLa cells
Concentration: 0.1; 0.5; 1; 3; 10 μM
Incubation Time: 1 h
Result: Induced a biphasic change in TBC1D2 fluorescence intensity within 1 h: levels decreased at 0.1 μM, rebounded to a 1.6-fold increase at 1 μM, then decreased again at 10 μM compared to control.

Apoptosis Analysis[1]

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2; 2.5 μM
Incubation Time: 24 h
Result: Induced a triphasic apoptotic response: the percentage of apoptotic cells increased from 4% (control) to 26% at 1.5 μM, decreased to 16% at 2 μM, then sharply rose to 94% at 2.5 μM.

Cell Cycle Analysis[1]

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2; 2.5 μM
Incubation Time: 24 h
Result: Induced a non-monotonic change in the G2/M phase fraction: the proportion increased from 11% (control) to 34% at 0.5 μM, decreased to 4% at 1 μM, then gradually rose to 54% at 2.5 μM.
In Vivo

TBC1D2-IN-1 (compound A1) (40 mg/kg; p.o.; every other day; 28 days) inhibits tumor growth inhibition rate in HeLa xenograft BALB/c nude mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c nude subcutaneously injected with HeLa cells[1]
Dosage: 40 mg/kg
Administration: p.o.; every other day; 28 days
Result: Achieved a 49% tumor growth inhibition rate.
Induced extensive areas of tumor necrosis via H&E staining.
Exhibited no significant body weight loss relative to controls.
Caused only mild, gefitinib-comparable histopathological alterations in major organs, including mild capillary wall thickening in lungs and occasional tubular swelling and edema in kidneys.
Molecular Weight

576.65

Formula

C34H35F3N2O3
SMILES

O=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CC/C1=C\C5=CC(C=CC(OCC6=CC=C(OC(F)(F)F)C=C6)=C7)=C7C=C5
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TBC1D2-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TBC1D2-IN-1AutophagyApoptosisCaspaseBcl-2 FamilyTBC1D2autophagycell cycle arrestcervical carcinomaRAB7AHeLa cellsA549anastasislysosomal membranesHepG2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TBC1D2-IN-1
Cat. No.:
HY-183772
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.